Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
  • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
  • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
  • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Definitions

• the instant invention relates to metal salts useful for treating 5 cyclooxygenase-2 ("COX-2") mediated conditions, to pharmaceutical compositions containing such salts as an active ingredient, to processes for preparing such salts and compositions, to methods of treatment of COX-2 mediated disorders comprising administering such compositions to a subject, and to the use of such compositions in the manufacture of medicaments.
• COX-2 cyclooxygenase-2
• celecoxib also known as 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1 H- pyrazol-1-yl]benzenesulfonamide.
• Celecoxib has a therapeutically and prophylactically useful selective COX-2 inhibitory effect, and has utility in treatment and prevention of COX-2 mediated disorder.
• International Patent Publication No. WO 00/32189 discloses that celecoxib has a crystal morphology which tends to form long, cohesive needles.
• WO 00/42021 discloses a solvated crystalline form of celecoxib and a 30 method for desolvation of that crystalline form.
• the forms of celecoxib generally have a low solubility in aqueous media (about 2 to about 5 ⁇ g/mL).
• Valdecoxib i.e., 4-(5-methyl-3-phenylisoxazol-4-yl) benzenesulfonamide
• U.S. Patent No. 5,633,272 is among another class of selective COX-2 inhibitory drugs.
• Valdecoxib is practically water insoluble.
• Parecoxib i.e., N-[[4-(5-methyl-3-phenylisoxazol-4- yl)phenyl]sulfonyl]propanamide
• Parecoxib is a prodrug of valdecoxib; parecoxib shows only very low in vitro inhibitory activity against COX-1 and COX-2 but upon administration, parecoxib is converted to valdecoxib.
• Sodium parecoxib (“Na parecoxib"), also disclosed in U.S. Patent No.
• Parenteral drug formulations have become a very important component in the arsenal of available drug delivery options, particularly for drugs having analgesic effect.
• parenteral routes of administration e.g., subcutaneous, intramuscular and intravenous injection
• parenteral administration of a drug typically results in attainment of a therapeutically effective blood serum concentration of the drug in a shorter time than is achievable by oral administration. This is especially true of intravenous injection, whereby the drug is placed directly in the bloodstream.
• parenteral administration can result in more predictable blood serum concentrations of a drug. For similar reasons, parenteral administration often permits dose reduction.
• Parenteral administration is generally the preferred method of drug delivery in emergency situations, and is also useful in treating subjects who are uncooperative, unconscious, or otherwise unable or unwilling to accept oral medication.
• Stable liquid parenteral parecoxib formulations are described in U.S. Patent Application Pub. No. US 2004/0127537 A1 .
• It is often desired that a parental drug formulation provides for a longer action compared to other formulations, thereby reducing the frequency of administration.
• a selective COX-2 inhibitory compound comprising a magnesium salt of parecoxib useful for treating a subject with a COX-2 mediated disorder.
• the term "treating a subject with a COX-2 mediated disorder” is mean fo embrace prophylactic administration of the instant compound to a subject with a likelihood of developing a COX-2 mediated disorder.
• the term "COX-2 mediated disorder” is meant to embrace conditions where COX-2 activity underlies a pathology or an unwelcome physical effect.
• the magnesium salt of parecoxib is magnesium diparecoxib ("Mg diparecoxib").
• the Mg diparecoxib of the present invention is crystalline.
• the Mg diparecoxib crystals are non- needle-like.
• the non-needle-like crystals of the present invention are cuboidal or polygonal.
• Mg diparecoxib of the present invention is in a pharmaceutical composition also comprising at least one excipient. Such dosage forms are useful for oral ingestion as a tablet, capsule, suspension, and the like.
• the pharmaceutically acceptable dosage form of the instant invention is a composition suitable for parenteral administration.
• the parenterally administrable composition of the instant invention is suitable for depot administration.
• Mg diparecoxib is in the form of a pharmaceutical composition further comprising a second active ingredient.
• a compound having the structure MX 1 (X 2 ) n wherein M is a metal cation selected from the group consisting of Ca 2+ , Zn 2+ , and K + ; X 1 is parecoxib anion; X 2 is selected from the group consisting of parecoxib anion and another pharmaceutically acceptable anion; and n is 0 when M is K + and n is 1 when M is Ca 2+ or Zn 2+ .
• the instant invention provides a depot formulation of a parecoxib salt that, when administered as a depot, results in therapeutic levels of valdecoxib.
• a parecoxib salt is selected from Mg diparecoxib, zinc diparecoxib ("Zn diparecoxib"), calcium diparecoxib (“Ca diparecoxib”), potassium parecoxib ("K parecoxib”), and Na parecoxib.
• the instant invention provides a depot composition of valdecoxib that, when administered as a depot to a subject in need thereof, results in therapeutic levels of valdecoxib.
• a depot composition of the instant invention wherein, upon injection into at least one parenteral site of a subject, . provides at least one of the following: [0026] (a) a therapeutic level of valdecoxib within about 10, alternatively about 5, or alternatively about 3 hours after depot administration; [0027] (b) a therapeutic level of valdecoxib for at least about 2, alternatively for at least about 3, or alternatively for at least about 4 days; [0028] (c) a time to reach a maximum blood serum concentration (T1/2max) of valdecoxib that is not greater than about 20, alternatively not greater than about 10, or alternatively not greater than about 3 hours after administration.
• T1/2max maximum blood serum concentration
• This invention also provides a method for preparing Mg diparecoxib, the method comprising an in situ crystallization method. [0030] This invention also provides a method for preparing Mg diparecoxib, the method comprising the step of precipitating Mg diparecoxib from parecoxib FA, for example, by reacting MgOH 2 with solubilized parecoxib FA.
• FIG. 1 shows the UV absorbance spectra of the supernatants from in situ crystallization of the parecoxib salts as described in Example 1.
• FIG. 2 shows a 600X magnification of Ca diparecoxib crystals.
• FIG. 3 shows a 600X magnification of Mg diparecoxib crystals.
• FIG. 4 shows time-dependant solubilization of Mg diparecoxib, parecoxib FA, and valdecoxib suspensions in a dissolution apparatus.
• FIG. 5 shows microscopy of parecoxib FA compositions formed as described in Example 4.
• FIG. 5 shows microscopy of parecoxib FA compositions formed as described in Example 4.
• FIG. 6 shows microscopy of Mg diparecoxib compositions formed as described in Example 4.
• FIG. 7 shows microscopy of valdecoxib compositions formed as described in Example 4.
• FIG. 8 shows plasma levels of valdecoxib after suspension of Example 4 were injected into dogs.
• FIG. 9 shows cumulative input rate of valdecoxib from Example 5.
• FIG. 10 shows plasma valdecoxib concentration with time following Mg diparecoxib depot administration to dogs.
• FIG. 11 shows theoretical plasma valdecoxib levels that are predicted to follow Mg diparecoxib depot administration to humans.
• a magnesium salt of parecoxib having the structure MgX 1 X 2 , wherein X 1 is parecoxib anion and X 2 is selected from the group consisting of parecoxib anion and another pharmaceutically acceptable anion.
• Suitable pharmaceutically acceptable anions include, but are not limited to, chloride, bromide, sulfate, phosphate, nitrate, acetate, propionate, succinate, glycolate, stearate, lactate, malate, tartrate, citrate, ascorbate, glutamate, benzoate, salicylate, methanesulfonate, and toluenesulfonate.
• the magnesium salt of parecoxib is substantially in the form of Formula I
• Mg diparecoxib is referred to herein as Mg diparecoxib.
• the term "substantially in the form of Formula I" is meant to embrace molecular forms wherein the parecoxib anion to magnesium cation molar ratio is between about 1.5 and about 2.5, preferably about 2.
• Mg diparecoxib is crystalline.
• magnesium salts of the present invention are non-needle-like crystals, for example, cuboidal or polygonal crystals.
• the Mg diparecoxib is of a form having a relatively low surface area to volume ratio (especially when compared to needle- like crystals).
• the term "relatively low,” in this context, means a surface area to volume ratio less than about 48 ⁇ m -1 , preferable less than about 24 ⁇ rrf 1 , more preferably less than about 12 ⁇ m -1 .
• the Mg diparecoxib crystals in another embodiment, in the absence of milling or sonication or the like, have an average particle size, using a Horiba Particle Sizer, of about 40 ⁇ m. In the absence of milling or sonication or the like, the crystals of the present invention have a D 90 (by mass) of less than about 100 ⁇ m, preferably less than about 60 ⁇ m, more preferably about 40 ⁇ m (based upon the longest length of the crystal).
• the crystals After 1 min sonication of an alternative embodiment, the crystals have an average particle size, using a Horiba Particle Sizer, of about 20 ⁇ m. Alternatively, such crystals have a D 90 (by mass) of less than about 60 ⁇ m, alternatively less than about 40 ⁇ m, alternatively about 20 ⁇ m (based upon the longest length of the crystal).
• Mg diparecoxib is precipitated from parecoxib FA, which may be prepared as described in U.S. Patent No. 5,932,598.
• parecoxib FA may be suspended or dissolved in a liquid.
• a 75 mM suspension of parecoxib FA may be made in ethanol.
• a magnesium salt e.g., Mg(OH) 2 , MgCI 2 or Mg
• Mg(OH) 2 may be suspended or dissolved in a second liquid.
• a 55 mM suspension of Mg(OH) 2 may be made in ethanol.
• the suspension or solution of parecoxib FA and a magnesium salt may be combined.
• three parts of the aforementioned 75 mM parecoxib FA suspension may be combined with two parts of the aforementioned 55 mM Mg(OH) 2 suspension.
• the molar ratio of parecoxib anion to the magnesium cation is 2 to 1 , alternatively the molar ratio is more than about one to one and less than about four to one.
• the combination may be agitated (e.g., stirred) for a period of time (e.g., for 10 minutes or more). During this agitation period, magnesium salt of parecoxib will precipitate. The precipitates may be collected, for example, by centrifugation or by evaporating the ethanol (e.g., in vacuo). Optionally, the crystals may be dried (e.g., at high vacuum).
• Magnesium diparecoxib may alternatively be prepared by in situ crystallization.
• Sodium parecoxib prepared as described in U.S. Patent No. 5,932,598, may be dissolved in a liquid.
• the liquid can be water, and optionally the liquid may be buffered.
• Na parecoxib may be dissolved in 15 mM Tris adjusted to a slightly basic pH (e.g., pH 8) to avoid formation of valdecoxib at a useful concentration (e.g., at 10-40 mg parecoxib FA equivalents/mL) to form a solution.
• This solution may be combined with a concentrated magnesium salt solution (e.g., MgCI 2 or MgSO ).
• the parecoxib solution and the magnesium salt solution may be combined such that the molar ratio of parecoxib anion to cation is greater than about 1 , optionally greater than about 1.5 or greater than about 2.
• the combination may be agitated (e.g., stirred) for a period of time (e.g., for about one to about 30 minutes or for overnight).
• the magnesium salt of parecoxib will precipitate.
• Mg diparecoxib precipitates may be separated from the solution, for example, by centrifugation or filtration, as described above.
• Other variations for preparing Mg diparecoxib are set forth below by way of working examples.
• K parecoxib can be made by adding KOH to parecoxib FA by the procedure taught above.
• a pharmaceutical compositions comprising Mg diparecoxib and one or more pharmaceutically acceptable excipients. Based upon the disclosure herein, one of skill in the art can select one or more pharmaceutically acceptable excipients selected according to the desired route of administration, desired plasma levels of valdecoxib, and desired duration of therapeutic levels of circulating valdecoxib.
• the instant composition comprises Mg diparecoxib in an amount of at least about 1 % by weight of the total composition weight, alternatively at least about 10% or at least about 20% by weight.
• These pharmaceutical compositions may be prepared in an oral dose unit in the form of discrete solid articles such as tablets, pills, hard or soft capsules, lozenges, sachets or pastilles; alternatively the composition can be in the form of a substantially homogeneous flowable mass, such as a particulate, powder, or granular solid or a liquid suspension, from which single dose units are measurably removable.
• these pharmaceutical compositions are in a form suitable for parenteral administration.
• parenteral administration encompasses injection and/or infusion of a composition into or through the skin of a subject, and includes, without limitation, intradermal, subcutaneous, intramuscular, intravenous, intramedullary, intra-articular, intraperitoneal, intralymphoid, intrasynovial, intraspinal, intrathecal, subdural, and intracardiac administration. Any known device useful for parenteral injection or infusion of drugs can be used to effect such administration.
• Parenterally-deliverable embodiments of the instant invention satisfy one or more, optionally three or more, optionally five or more, optionally seven or more, or optionally nine or more of the following criteria: sterility, low endotoxin level, defined particle size range, no "caking" during shelf life, easy redispersion with mild shaking, slow rate of settling after redispersion, homogeneity of suspension after redispersion, syringeable and injectable through narrow gauge needle, formulation isotonicity and pH close to physiologic range, physical particle stability (e.g., no polymorphism or crystal growth), and chemical stability.
• Parenterally deliverable compositions of the instant invention comprise Mg diparecoxib in a therapeutically effective amount.
• compositions may also comprise one or more of the following: a parenterally acceptable buffer for adjusting and/or maintaining pH of the composition; an isotonicity agent; a suspending agent to reduce undesired settling out of Mg diparecoxib in liquid compositions; and a solubilizing agent.
• a solubilizing agent can comprise, for example, at least one cyclodextrin. Suitable cyclodextrins include a- cyclodextrins and ?-cyclodextrins (also referred to herein as -CD).
• the cyclodextrins are yS-cyclodextrins.
• these optional cyclodextrin derivatives are those wherein the C 2-6 alkylene is a C 3 or C 4 alkylene.
• sulfoalkylether ⁇ -cyclodextrin for example, sulfobutylether- ?-cyclodextrin having an average substitution of about 4 to about 8 and preferably about 5 to about 7, for example, about 6.4 sulfobutyl ether linkages (i.e., sulfobutyl ether 6 . 4 - ?-cyclodextrin).
• composition of the instant invention can comprise at least one non-aqueous solubilizing agent such as a polyethylene glycol, ethanol, dimethylacetamide (DMAC), a propylene glycol, and mixtures thereof.
• Compositions of the instant invention optionally comprise a isotonicity agent, for example, NaCl, sorbitol, mannitol, dextrose, polyethylene glycols ("PEGs”), phosphate buffers, methyl and propyl parabens, polyethylene glycols, carboxymethylcelluloses, alginate, polyvinyl pyrrolidones, or polysorbates.
• a non-aqueous solubilizing agent such as a polyethylene glycol, ethanol, dimethylacetamide (DMAC), a propylene glycol, and mixtures thereof.
• Compositions of the instant invention optionally comprise a isotonicity agent, for example, NaCl, sorbitol, mannitol, dextrose, poly
• composition in powder form.
• the powder form is optionally reconstitutable in a parenterally acceptable solvent liquid, optionally an aqueous liquid, to form a solution suitable for injection.
• the parenterally deliverable composition in powder form can be prepared by a process comprising a step of removing water from an aqueous solution (by, for example, lyophilization) comprising Mg diparecoxib and optionally one or more buffers, a isotonicity agent, and a suspending agent to form a readily reconstitutable powder.
• the invention is an article of manufacture comprising a sealed vial having contained therewithin a sterile, parenterally deliverable composition of the instant invention in powder form.
• the invention can optionally contain a useful volume of a solvent (e.g., water) sequestered from the powder form in a compartment that allows mixing of the water and the powder form before use without opening the sealed vial.
• a solvent e.g., water
• the invention is an injectable solution prepared by reconstitution of the composition.
• the invention is an article of manufacture comprising a sealed vial having contained therewithin a unit dosage amount of the composition in a sterile condition.
• the parenterally deliverable composition of the instant invention is suitable for depot administration.
• a depot administration preferably delivers a therapeutically effective dose for a sustained period of time, for example, at least about two days, optionally at least about three days, optionally at least about four days, or optionally at least about five days.
• a "depot" is a pharmaceutical composition containing a therapeutically active agent that is suitable for administration by implantation or injection into a local site that results in a gradual release (for example, release over a few hours or a few days) of the active agent into circulation. Release of the active agent is modulated by the nature of the site injected or implanted, the solubility of the active agent, and the precise composition of the depot.
• depot administration means the administration by implantation or injection, for example, subcutaneous, intramuscular, intradermal, and intra-articular administration.
• a depot administration is to be contrasted with, for example, an intra venous injection that results in rapid systemic delivery of the active agent (for example, within minutes of injection).
• the depot compositions of the instant convention can contain Mg diparecoxib and a means for stabilizing and/or controlling solubilization rate of the Mg diparecoxib.
• Such stabilizing and/or controlling means can be selected from suitable polymeric or hydrophobic materials or ion-exchange resins.
• an emulsion can be produced from Mg diparecoxib using an acceptable oil to stabilize or control release of Mg diparecoxib.
• Pharmaceutical compositions of the instant invention are characterized by at least one feature selected from the group consisting of steady extended release, useful release rate, minimal pain on injection, no local toxicity due to depot, a duration of action correlated with dose, and a correlation between in vitro and in vivo release.
• Depots of the instant invention contain Mg diparecoxib at a concentration useful for parenteral administration that results in a therapeutic level of valdecoxib. Such a useful concentration is about 40 to 500 mg/mL, for example, about 80 mg/mL to about 280 mg/mL.
• Another embodiment of the present invention is a method of administering Mg diparecoxib in depot formulation Such a method delivers an amount of Mg diparecoxib in an amount of about 40 mg to about 500 mg, optionally 60 mg to about 400 mg or optionally about 80 mg to about 280 mg.
• the depot composition of the instant invention contains a second therapeutically active agent.
• the term "active agent" may refer to a drug or a prodrug.
• the second active agent is an analgesic, an anti-pyretic, and/or an anti-inflammatory compound.
• the second active agent is a selective COX-2 inhibitor; optionally the selective COX-2 inhibitor is a valdecoxib prodrug or valdecoxib.
• the second active agent delivers a therapeutic level of valdecoxib more rapidly than does Mg diparecoxib in the same embodiment.
• such a composition comprises Mg diparecoxib and a second active agent in an amount such that, when administered as a depot, therapeutic levels of circulating valdecoxib attain the predicted therapeutic need over a period of two or more days.
• Examples of selective COX-2 inhibitors useful as the second active agent are valdecoxib, celecoxib, rofecoxib, etoricoxib, lumiracoxib, and parecoxib, or salts thereof.
• Examples of such embodiments are a dosage form comprising Mg diparecoxib and Na parecoxib; Mg diparecoxib and Ca diparecoxib; Mg diparecoxib and Zn diparecoxib; Mg diparecoxib and K parecoxib; and Mg diparecoxib and valdecoxib.
• physicochemical properties of salts of the present invention e.g., Mg diparecoxib, Ca diparecoxib, Zn diparecoxib, and K parecoxib
• valdecoxib contribute, in part, to a dosage form with different pharmacokinetic properties.
• pharmacokinetic properties include, by way of example, dissolution rate, bioabsorption rate, time to reach maximum concentration (T max ), the duration of time that therapeutic (or other) levels are sustained; the terminal half-life (T ⁇ / 2 ); and maximum concentration (C m ax).
• a skilled artisan is able to combine compounds of the present invention in absolute and relative amounts such that, when formulated and administered as a depot, any desired circulating levels of valdecoxib can be achieved, even if such desired levels predictably change with time following administration.
• a first therapeutic level for example, 75 ng valdecoxib/mL plasma. It can be desirable to sustain such first therapeutic level for a certain first period of time, for example, two days.
• a second therapeutic level for a second period of time for example, 25 ng valdecoxib/mL plasma for four days.
• a third valdecoxib level for a third period of time can be a changing level (for example, 25 ng valdecoxib/mL plasma) decreasing to 0 ng valdecoxib/mL plasma over the course of the third period of time (for example, two days).
• compositions of the invention are useful in subjects for treatment and prevention of a very wide range of disorders mediated by COX-2, including but not restricted to disorders characterized by inflammation, pain and/or fever. Such composition possess the additional benefit of having significantly less harmful side effects than compositions of conventional NSAIDs that lack selectivity for COX-2 over COX-1.
• compositions of the invention have reduced potential for gastrointestinal toxicity and gastrointestinal irritation, including upper gastrointestinal ulceration and bleeding, by comparison with compositions of conventional NSAIDs.
• compositions of the invention are particularly useful as an alternative to conventional NSAIDs where such NSAIDs are contraindicated, for example, in subjects with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; gastrointestinal bleeding, coagulation disorders including anemia such as hypoprothrombinemia, hemophilia or other bleeding problems; kidney disease; or in subjects prior to surgery or subjects taking anticoagulants.
• compositions of the instant invention are useful in treating a condition or disorder where treatment with a COX-2 inhibitory drug is indicated. More preferred uses include treatment for an acute condition (e.g., a condition where treatment is need for a period of several days to several weeks). [0083] Compositions of the instant invention are useful in treatment of pain, including but not limited to perioperative pain, postoperative pain, post-oral surgery pain, post-general surgery pain, post-orthopedic surgery pain, dental pain, muscular pain, and pain resulting from cancer.
• perioperative pain i.e., pain associated with the surgical procedure itself and the more intense and/or acute pain following the surgery
• post operative pain i.e., pain following the more intense and/or acute pain phase
• compositions of the instant invention are useful for relief of pain, fever and inflammation in a variety of conditions including rheumatic fever, influenza and other viral infections including common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns, radiation damage, and trauma following surgical and dental procedures.
• Contemplated compositions are useful to treat a variety of arthritic disorders, including but not limited to rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis.
• compositions are useful for treating and preventing inflammation-related cardiovascular disorders, including vascular diseases, coronary artery disease, aneurysm, vascular rejection, arteriosclerosis, / atherosclerosis including cardiac transplant atherosclerosis, myocardial infarction, embolism, stroke, thrombosis including venous thrombosis, angina including unstable angina, coronary plaque inflammation, bacterial-induced inflammation including Chlamydia-induced inflammation, viral induced inflammation, and inflammation associated with surgical procedures such as vascular grafting including coronary artery bypass surgery, revascularization procedures including angioplasty, stent placement, endarterectomy, or other invasive procedures involving arteries, veins and capillaries.
• vascular diseases including coronary artery disease, aneurysm, vascular rejection, arteriosclerosis, / atherosclerosis including cardiac transplant atherosclerosis, myocardial infarction, embolism, stroke, thrombosis including venous thrombosis, angina including unstable angina, coronar
• compositions of the instant invention are useful in prevention and treatment of benign and malignant tumors and neoplasia including cancer, such as colorectal cancer, brain cancer, bone cancer, epithelial cell-derived neoplasia (epithelial carcinoma) such as basal cell carcinoma, adenocarcinoma, gastrointestinal cancer such as lip cancer, mouth cancer, esophageal cancer, small bowel cancer, stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer, skin cancer such as squamous cell and basal cell cancers, prostate cancer, renal cell carcinoma, and other known cancers that effect epithelial cells throughout the body.
• cancer such as colorectal cancer, brain cancer, bone cancer, epithelial cell-derived neoplasia (epithelial carcinoma) such as basal cell carcinoma, adenocarcinoma, gastrointestinal cancer such as lip cancer, mouth cancer, esophageal cancer, small bowel cancer
• Neoplasias for which compositions of the invention are contemplated to be particularly useful are gastrointestinal cancer, Barrett's esophagus, liver cancer, bladder cancer, pancreatic cancer, ovarian cancer, prostate cancer, cervical cancer, lung cancer, breast cancer and skin cancer.
• Such compositions can also be used to treat fibrosis that occurs with radiation therapy.
• Such compositions can be used to treat subjects having adenomatous polyps, including those with familial adenomatous polyposis (FAP). Additionally, such compositions can be used to prevent polyps from forming in subjects at risk of FAP.
• Subjects undergoing treatment with a composition of the invention can be routinely monitored by any of the methods well known in the art to determine effectiveness of therapy.
• Parecoxib salts of the instant invention e.g., Mg diparecoxib, Zn diparecoxib, Ca diparecoxib, and K parecoxib
• valdecoxib e.g., Mg diparecoxib, Zn diparecoxib, Ca diparecoxib, and K parecoxib
• a therapeutically effective dose of parecoxibs of the instant invention is one that delivers a therapeutically effective circulating dose of valdecoxib.
• therapeutic levels typically are at least about 20 ng/mL plasma, for example, about 25 to about 75 ng/mL.
• Therapeutic methods of the instant invention further include combination therapies of parecoxib or a composition of the invention with one or more drugs selected from opioids and other analgesics, including narcotic analgesics, Mu receptor antagonists, Kappa receptor antagonists, non-narcotic (i.e., non-addictive) analgesics, monoamine uptake inhibitors, adenosine regulating agents, ca ⁇ nabinoid derivatives, Substance P antagonists, neurokinin- 1 receptor antagonists and sodium channel blockers, among others.
• Preferred combination therapies comprise use of a composition of the invention with one or more compounds selected from aceclofenac, acemetacin, e-acetamidocaproic.
• Therapeutic methods of the instant invention further include combination therapies of the parecoxib salts of the instant invention with one or more antineoplastic agents (e.g., antineoplastic topoisomerase II inhibitors, antineoplastic antimicrotubule agents, antineoplastic alkylating agents, antineoplastic antimetabolites, and antineoplastic topoisomerase I inhibitors).
• antineoplastic agents e.g., antineoplastic topoisomerase II inhibitors, antineoplastic antimicrotubule agents, antineoplastic alkylating agents, antineoplastic antimetabolites, and antineoplastic topoisomerase I inhibitors.
• Antineoplastic topoisomerase II inhibitors can, by way of example, be anthracycline compounds (e.g., doxorubicin, daunomycin, methoxy-morpholino- doxorubicin, epirubicin idarubicin and nemorubicin); anthraquinone compounds (e.g., mitoxantrone and losoxantrone); and podophillotoxine compounds (e.g., etoposide and teniposide).
• Antimicrotubule agents can, by way of example, be taxane compounds (e.g., paclitaxel and docetaxel) and vinca alkaloids (e.g., vinblastine and vinorelbine).
• Alkylating agents can, by way of example, be cyclophosphamide, ifosfamide, chlorambucil, and melphalan.
• Antineoplastic antimetabolite agents can, by way of example, be 5-fluorouracil, capecitabine, gemcitabine, methotrexate and edatrexate.
• Antineoplastic topoisomerase I inhibitors can, by way of example, be topotecans, irinotecans, and 9- nitrocamptothecin.
• the term "subjects", as objects of treatment with compositions of the instant invention means animals. Preferably such animals are humans or companion animals, exotic animals, farm animals, and the like, particularly mammals.
• the term "in vivo administration” means administration to a subject by oral or parenteral route.
• the instant invention is further directed to a therapeutic method of treating a condition or disorder where treatment with a COX-2 inhibitory drug is indicated, the method comprising parenteral administration of a composition of the invention to a subject in need thereof.
• the dosage regimen to prevent, give relief from, or ameliorate the condition or disorder is determined in accordance with a variety of factors. These include the type, age, weight, sex, diet and medical condition of the subject and the nature and severity of the disorder. Thus, the dosage regimen actually employed can vary widely.
• Compounds of the present invention are salts of parecoxib, a prodrug of valdecoxib, which is a selective COX-2 inhibitor.
• cyclooxygenase-1 and “COX-1” used interchangeably herein refer to the constitutive isoform of the enzyme cyclooxygenase.
• cyclooxygenase- 2 and “COX-2 as used interchangeably herein refer to the inducible isoform of the enzyme cyclooxygenase.
• the terms “cyclooxygenase-2 selective inhibitor” and “COX-2 selective inhibitor” refer to a compound that inhibits COX-2 more than it inhibits COX-1 in an in vitro recombinant enzyme assay.
• cyclooxygenase-2 inhibitor or "COX-2 inhibitor” refers to any compound which inhibits the COX-2 enzyme, without regard to the extent to which it inhibits COX-1.
• COX-2 selective inhibitors useful in the present invention are those compounds that have a COX-2 IC 5 o of less than about 0.2 ⁇ M, and also have a selectivity ratio of COX-2 inhibition over COX-1 inhibition of at least 50 or alternatively, at least 100.
• the COX-2 selective inhibitor compounds have a COX-1 IC 50 of greater than about 1 ⁇ M or alternatively, greater than 10 ⁇ M.
• Example 1 Preparation of Mg diparecoxib, Zn diparecoxib, Ca diparecoxib, and K parecoxib [0098]
• Magnesium diparecoxib, Zn diparecoxib, Ca diparecoxib, and K parecoxib were prepared using in situ crystallization. Briefly, solutions of Na parecoxib were prepared in water for injection ("WFI") at 10 mg/mL. Salt solutions were prepared in WFI using KCl, CaCI 2 , MgCI 2 , or ZnCI 2 . Stoichiometric excess of the chloride salt solutions were added individually to Na parecoxib solutions, and WFI was added to a control solution of Na parecoxib.
• WFI water for injection
• Example 2 Preparation of Mg diparecoxib and Ca diparecoxib [00102] Since Ca diparecoxib and Mg diparecoxib exhibited the lowest solubilities of the parecoxib salts examined in Example 1 , these two salt forms of parecoxib were selected for further investigation. [00103] A series of compositions of Ca diparecoxib and Mg diparecoxib were prepared by in situ crystallization, starting from solutions of Na parecoxib. A slightly basic pH was selected for in situ crystallization in order to avoid formation of parecoxib FA, and to obtain compositions with near physiologic pH. [00104] Sodium phosphate was tested for compatibility with the CaCl 2 and MgCI 2 reagents.
• Calculated volumes of 1 M CaCI 2 and MgCI 2 salt solutions were added to buffered solutions of Na parecoxib to provide 0.5, 1 , 2, and 4 molar equivalents of Ca 2+ and Mg 2+ relative to parecoxib, as per Table I.
• Control compositions were also prepared wherein the salt solutions were added to Tris buffer with no parecoxib present, or where water was added to Na parecoxib solution instead of salt. Visible precipitation was observed in each case soon after addition of the salt solutions to Na parecoxib solutions, and no precipitation was observed for the control compositions. The compositions were allowed to stir overnight before further analysis. [00106] After overnight stirring, visual observations were made.
• Optical microscopy of the suspension compositions showed that needle like crystals were formed for Ca diparecoxib (Fig 2), whereas Mg diparecoxib crystals exhibited cuboidal/polygonal morphology (Fig 3).
• the latter crystal morphology is relatively more desirable for several reasons: reduced surface area for dissolution (leading to slow release), easier syringeability, and reduced likelihood of pain at injection site.
• Example 3 In vitro solubility of Mg diparecoxib [00109] In vitro solubility of dry powder of Mg diparecoxib was determined in various dissolution media and compared to solubility of parecoxib FA and valdecoxib. As shown in Table II, solubility of dry powder of Mg diparecoxib in acidic media was similar to parecoxib FA, solubility of Mg diparecoxib in phosphate buffer at near-physiologic pH was substantially higher than that of parecoxib FA.
• Example 4 Compositions of Mg diparecoxib, parecoxib FA, and valdecoxib [00111] Magnesium diparecoxib, parecoxib FA, and valdecoxib were formulated into pharmaceutically acceptable suspensions set forth in Table IV.
• the starting material for valdecoxib was prepared by in situ crystallization using controlled addition of a valdecoxib/PEG 400 solution to a sterile filtered aqueous buffer (set forth below).
• the starting material for parecoxib FA was prepared by in situ crystallization by controlled addition of hydrochloric acid to a sterile filtered solution of Na parecoxib.
• the starting material for Mg diparecoxib composition was prepared by in situ crystallization by controlled addition of MgCI 2 (at a slight excess) to a sterile filtered solution of Na parecoxib.
• the crystals of Mg diparecoxib have the surprising result of having properties especially favorable for depot formulation, that is, reduced surface area for dissolution (leading to slow release), easier syringeability, and less pain at injection site.
• Valdecoxib crystals were cuboidal or polygonal. Average particle size (using Horiba Particle Sizer) was about 75 ⁇ m. After 1 min sonication, average particle size was about 18 ⁇ m.
• Example 5 Screening of Mg diparecoxib compositions [00113] Ten Mg diparecoxib suspension compositions were prepared at a 20 mL volume and at 40 mg/mL concentration to evaluate effect of different excipients, as described in Table V.
• compositions were prepared by in situ crystallization, starting from solutions of Na parecoxib in Tris buffer. Two different reagents (MgCI 2 and MgSO 4 ) were evaluated as source of magnesium ions for the in situ salt formation. Five compositions were prepared with each of these two reagents, and with various excipients.
• compositions gave white suspensions were obtained. During preparation, nucleation of the compositions was necessary with a few ⁇ L of a Mg diparecoxib composition prepared separately at a smaller 5 mL scale (no nucleation was necessary at the smaller scale). [00115] The suspension compositions were analyzed by pH, UV absorbance in supernatant, redispersability, syringeability, sedimentation volume, dose transfer accuracy and optical microscopy. A summary of the results is provided in Table VI.
• Example 6 Pharmacokinetic study of Mg diparecoxib, parecoxib FA, and valdecoxib compositions in dogs [00116] The suspensions described in Example 4 were injected in dogs and serum levels of valdecoxib were measured at the times indicated in Table VII and Figure 8. Table VII
• composition vials were also stored at different temperature conditions for an informal stability evaluation. The analytical results indicated that the composition was stable at room temperature for at least 4 weeks.
• the composition was successfully administered to dogs by intramuscular injection. Plasma levels of parecoxib and its active metabolite valdecoxib were monitored up to 4 days. Significant plasma concentrations of valdecoxib were observed for at least 3 days from the Mg diparecoxib suspension composition as shown in Figure 10. For comparison, a simulated pharmacokinetic profile from an equivalent dose of Na parecoxib given intravenously is also shown.
• Example 8 Simulated human plasma concentration - time profiles for Mg diparecoxib
• Human plasma concentration of valdecoxib were simulated based upon dog pharmacokinetic analyses. Similar absorption rate for humans as observed in dogs. If absorption is strictly blood / plasma flow dependent, plasma levels may be 10-50% lower. The half life of valdecoxib is -1.4 h in dogs versus -7.4 h in humans. The minimum therapeutic concentration of valdecoxib is approx 50 ng/mL in humans (from PK studies with oral Valdecoxib). Such simulation is shown in Figure 11.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Pain & Pain Management (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Rheumatology (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34748827

Family Applications (1)

Country Status (5)

Families Citing this family (1)

Family Cites Families (4)

• 2004
  • 2004-12-13 CA CA002551523A patent/CA2551523A1/en not_active Abandoned
  • 2004-12-13 BR BRPI0417197-7A patent/BRPI0417197A/pt not_active Application Discontinuation
  • 2004-12-13 EP EP04806386A patent/EP1708700A1/de not_active Withdrawn
  • 2004-12-13 JP JP2006546376A patent/JP2007517013A/ja not_active Withdrawn
  • 2004-12-13 WO PCT/IB2004/004203 patent/WO2005065684A1/en not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events